Patients with atrial fibrillation at risk for stroke: OCEANIC-AF study stopped early due to inferior efficacy of Asundexian versus Apixaban
OCEANIC-AF, a phase III study investigating Asundexian compared to Apixaban, a direct oral anticoagulant, in patients with atrial fibrillation at risk for stroke is being stopped early.
This decisio ...
read article